ERBB2 and neoplasm: For the tumor site (ii) in Fig. 6(b), which was treated with an anti-HER2 antibody to block the HER2 receptor, distinct SERS bands at 1324 and 1633 cm−1 corresponding to the anti-EGFR-FAF610-SERSFITC dots were observed, without the bands of the anti-HER2-FAF610-SERSRITC dots at 1285 and 1648 cm−1.